WHO officially classified Hepatitis D virus as carcinogenic

Source: BS

Context: The World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) have officially classified Hepatitis D virus (HDV) as carcinogenic, placing it in Group 1 — known causes of liver cancer, alongside Hepatitis B and C.

About WHO officially classified Hepatitis D virus as carcinogenic:

• What is Hepatitis D Virus (HDV)? Hepatitis D is a blood-borne viral infection that requires the presence of Hepatitis B virus (HBV) to replicate. HDV cannot exist independently and occurs as co-infection (simultaneous with HBV) or superinfection (after existing HBV).

• Hepatitis D is a blood-borne viral infection that requires the presence of Hepatitis B virus (HBV) to replicate.

• HDV cannot exist independently and occurs as co-infection (simultaneous with HBV) or superinfection (after existing HBV).

• Who Classified It as Carcinogenic? Classified by: WHO (World Health Organization) IARC (International Agency for Research on Cancer) Group 1 Category: Proven carcinogens in humans. Key Features of Hepatitis D and HBV Infection: Affects nearly 12 million people, i.e., ~5% of chronic HBV carriers globally. High prevalence in Asia, Africa, and the Amazon Basin. It also affects injection drug users and dialysis patients. Symptoms: Fatigue, jaundice, nausea, abdominal pain, dark urine — often ignored or misdiagnosed. Transmission: Through infected blood, unprotected sex, unsafe injections, and vertical transmission (mother-to-child). Why HDV is Classified as Cancer-Causing? Worsens HBV Outcomes: Co-infection increases liver cancer risk by 2–6 times vs. HBV alone. Rapid Liver Damage: Up to 75% develop cirrhosis in 15 years, compared to 50% in HBV-only cases. Aggressive Progression: Fast-tracked development of fibrosis and liver failure in younger populations. HDV hijacks HBV’s replication machinery, amplifying viral and oncogenic load. Treatment Landscape: No HDV-specific vaccine and HBV vaccine is the only preventive measure for both. Bulevirtide (approved in Europe) shows promise, used alongside pegylated interferon. HBV managed with lifelong antivirals and HDV therapies are still limited and expensive. WHO reports critical gaps in testing: Only 13% of HBV and 36% of HCV cases diagnosed. Treatment rates remain as low as 3% for HBV and 20% for HCV (2022 data).

• Classified by: WHO (World Health Organization) IARC (International Agency for Research on Cancer)

• WHO (World Health Organization)

• IARC (International Agency for Research on Cancer)

• Group 1 Category: Proven carcinogens in humans. Key Features of Hepatitis D and HBV Infection: Affects nearly 12 million people, i.e., ~5% of chronic HBV carriers globally. High prevalence in Asia, Africa, and the Amazon Basin. It also affects injection drug users and dialysis patients. Symptoms: Fatigue, jaundice, nausea, abdominal pain, dark urine — often ignored or misdiagnosed. Transmission: Through infected blood, unprotected sex, unsafe injections, and vertical transmission (mother-to-child).

• Key Features of Hepatitis D and HBV Infection:

• Affects nearly 12 million people, i.e., ~5% of chronic HBV carriers globally.

• High prevalence in Asia, Africa, and the Amazon Basin. It also affects injection drug users and dialysis patients.

• Symptoms: Fatigue, jaundice, nausea, abdominal pain, dark urine — often ignored or misdiagnosed.

• Transmission: Through infected blood, unprotected sex, unsafe injections, and vertical transmission (mother-to-child).

• Why HDV is Classified as Cancer-Causing? Worsens HBV Outcomes: Co-infection increases liver cancer risk by 2–6 times vs. HBV alone. Rapid Liver Damage: Up to 75% develop cirrhosis in 15 years, compared to 50% in HBV-only cases. Aggressive Progression: Fast-tracked development of fibrosis and liver failure in younger populations. HDV hijacks HBV’s replication machinery, amplifying viral and oncogenic load.

• Worsens HBV Outcomes: Co-infection increases liver cancer risk by 2–6 times vs. HBV alone.

• Rapid Liver Damage: Up to 75% develop cirrhosis in 15 years, compared to 50% in HBV-only cases.

• Aggressive Progression: Fast-tracked development of fibrosis and liver failure in younger populations.

• HDV hijacks HBV’s replication machinery, amplifying viral and oncogenic load.

• Treatment Landscape: No HDV-specific vaccine and HBV vaccine is the only preventive measure for both. Bulevirtide (approved in Europe) shows promise, used alongside pegylated interferon. HBV managed with lifelong antivirals and HDV therapies are still limited and expensive. WHO reports critical gaps in testing: Only 13% of HBV and 36% of HCV cases diagnosed. Treatment rates remain as low as 3% for HBV and 20% for HCV (2022 data).

• No HDV-specific vaccine and HBV vaccine is the only preventive measure for both.

• Bulevirtide (approved in Europe) shows promise, used alongside pegylated interferon.

• HBV managed with lifelong antivirals and HDV therapies are still limited and expensive.

• WHO reports critical gaps in testing: Only 13% of HBV and 36% of HCV cases diagnosed. Treatment rates remain as low as 3% for HBV and 20% for HCV (2022 data).

• Only 13% of HBV and 36% of HCV cases diagnosed.

• Treatment rates remain as low as 3% for HBV and 20% for HCV (2022 data).